Drug intelligence / Profile preview

PRDM1-T-DDS

Development stage
Preclinical
Lead developer
ARIZ Precision Medicine
Modality
Nanoparticles → Drug Delivery Systems
Administration
Intravenous
01

Overview

ARIZ Precision Medicine is developing PRDM1-T-DDS, a nanotechnology-based targeted drug delivery system (T-DDS) designed to target PRDM1 (PR domain zinc finger protein 1). PRDM1, also known as BLIMP-1, is a transcriptional repressor that plays a vital role in the differentiation of B cells into plasma cells and is implicated in the progression of several malignancies, including colon cancer, multiple myeloma, and various lymphomas. The T-DDS platform aims to enhance the precision of therapy by delivering payloads directly to cells expressing the PRDM1 target, thereby reducing systemic toxicity. Currently in preclinical development, the program has achieved in vitro proof-of-principle (POP) in colon cancer and myeloma models, while the lymphoma indication is in the target identification phase.

Other names
PRDM1 Targeted Drug Delivery SystemPRDM-1 Targeted Drug Delivery SystemPRDM 1 Targeted Drug Delivery System

Beyond the preview

Go deeper on PRDM1-T-DDS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRDM1-T-DDS.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call